Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria

Enrolling by invitation

Conditions studied: Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection, Mycobacterium Infections, Mycobacterium; Pulmonary

In brief

About 10 people with cystic fibrosis (CF) and persistent Nontuberculosis mycobacteria (NTM) infection despite treatment will be screened to find out if their NTM infection has at least one mycobacteriophage that is effective in killing the mycobacteria. Individuals who are found to have at least one phage will be offered assistance in pursuing FDA approval for treatment via expanded-access Individual New Drug (IND) for compassionate-use. They will receive phage treatment for 1 year along with their guideline-based antibiotics for NTM. Individuals who are not identified as having a phage match will be followed as they continue to receive guideline based antibiotic therapy for 1 year. All subjects, including those who do not have a phage match will continue to be observed for the duration of the study, or about 1 year.

Key facts

Study ID

NCT06262282

Run by

National Jewish Health

People needed

10

Starts

2024-02-05

Expected to finish

2028-12-31

Last updated by the study team

2025-05-21

Who can join

Age: 6 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent (and assent when applicable) obtained from participant or participant's legal representative
• Enrolled in the CFF Patient Registry (CFF PR)
• Be willing to adhere to study procedures in the context of clinical care, and other protocol requirements
• Male or female participant ≥ 6 years of age at enrollment who are able to reliably expectorate sputum and/or willing to undergo sputum induction (if necessary)
• Diagnosis of CF consistent with the 2017 CFF Guidelines
• NTM pulmonary disease on treatment with guideline-based antibiotics for >12 months without consistent conversion of airway cultures to negative.
• Physician intention to treat NTM with phage therapy (if susceptible)
• Be willing and able to continue guideline-based antibiotics for NTM concurrent with phage.
• Documentation of a sufficient number of NTM cultures with a sufficient proportion of positive cultures in the interval 12 months prior to initiation of phage to allow for a within-subject power ≥0.80 to detect a difference in the percent positive NTM cultures in the interval 6-18 months following initiation of phage.

You may not qualify if…

• Pregnant or breastfeeding
• Prior or ongoing phage therapy for the species of NTM under consideration.
• History of solid organ or hematological transplantation
• Has any other condition that, in the opinion of the Site Investigator/designee, would preclude informed consent or assent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives

Where it is running

• University of Alabama — Birmingham, Alabama, United States
• Children's Hospital of Los Angeles — Los Angeles, California, United States
• University of California — San Diego, California, United States
• Childrens Hospital Colorado — Denver, Colorado, United States
• National Jewish Health — Denver, Colorado, United States
• University of Florida — Gainesville, Florida, United States
• Northwestern University — Chicago, Illinois, United States
• John Hopkins University — Baltimore, Maryland, United States
• Boston Childrens Hospital — Boston, Massachusetts, United States
• University of Michigan — Ann Arbor, Michigan, United States
• Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire, United States
• Columbia University — New York, New York, United States
• University of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States
• Nationwide Children's Hospital — Columbus, Ohio, United States
• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States
• Southwestern Medical Center at Dallas — Dallas, Texas, United States
• University of Vermont — Burlington, Vermont, United States
• University of Washington — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.